Evaluation of enhanced peritoneum permeability in methylglyoxal-treated rats as a diagnostic method for peritoneal damage.
OBJECTIVE
As peritoneal damage in long-term peritoneal dialysis therapy is a major problem correlated to patient prognosis, diagnosis of peritoneal damage is important. To develop a diagnostic method for peritoneal damage, we focused on hyperpermeability across the peritoneum in a pathogenic peritoneal damage condition. In this study, disposition characteristics of an intraperitoneally injected marker substance in peritoneal damaged rats were analyzed.


METHODS
Peritoneal damaged rats were prepared by intraperitoneal injection of a glucose degradation product, methylglyoxal (MGO), for five or ten consecutive days. Phenolsulfonphthalein (PSP), as a marker substance, was intraperitoneally or intravenously injected into MGO-treated rats. Subsequently, the PSP disposition characteristics were pharmacokinetically analyzed.


RESULTS
In both cases of 5 and 10 days treatment of MGO, absorption of PSP after intraperitoneal injection was significantly enhanced. Plasma concentration and urinary excretion of PSP in MGO-treated rats were also higher than those in saline-treated rats in the early phase. On the contrary, there was no significant difference in terms of the pharmacokinetic parameters of intravenously injected PSP in saline- or MGO-treated rats. These results indicated that intraperitoneally injected MGO primarily acts on the peritoneal membrane; therefore, the peritoneal permeability of the marker substance was enhanced.


CONCLUSIONS
We demonstrated that pharmacokinetic analysis of peritoneum permeability might be a potent diagnostic method for peritoneal damage in experimental animals and patients receiving peritoneal dialysis.
Fumoto
Shintaro
S
Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan. sfumoto@nagasaki-u.ac.jp
Nakashima
Yukiko
Y
Nishida
Koyo
K
Kodama
Yukinobu
Y
Nishi
Junya
J
Nakashima
Mikiro
M
Sasaki
Hitoshi
H
Otsuka
Noboru
N
Nakamura
Junzo
J
D000818:Animals; D007202:Indicators and Reagents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D010532:Peritoneal Diseases / Q000139:chemically induced / Q000175:diagnosis* / Q000378:metabolism*; D010539:Permeability; D010637:Phenolsulfonphthalein / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011765:Pyruvaldehyde; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution
D007202:Indicators and Reagents; D011765:Pyruvaldehyde; D010637:Phenolsulfonphthalein